Takeda, Sucampo Make Amitiza Deal Global
This article was originally published in PharmAsia News
Executive Summary
Sucampo Pharmaceuticals will get $14 million up front and could earn up to $35 million in milestone fees based on certain sales targets in exchange for giving Takeda Pharmaceutical global rights to the constipation drug Amitiza, versus the partners' prior agreement.